SIM
DNLI icon

Sonora Investment Management’s Denali Therapeutics DNLI Stock Holding History

Sonora Investment Management’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		$31K Hold
619
– – ﹤0.01% 517
2021
Q2 		$49K Buy
+619
New +$38.3K 0.01% 397

Other funds holding DNLI

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $53.5M AUM 80.67% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Sonora Investment Management's DNLI Position: Q3 2021 in Review

Sonora Investment Management held its Denali Therapeutics (DNLI) position steady in Q3 2021 at 619 shares worth $31K. The position accounts for ﹤0.01% of the portfolio, ranked #517.

Sonora Investment Management first reported a position in DNLI in Q2 2021 and has held it in 2 quarters since. The position peaked at $49K in Q2 2021. 214 funds tracked by Wall St. Rank hold DNLI as of Q3 2021.

  • Sonora Investment Management held 619 shares of Denali Therapeutics worth $31K as of Q3 2021.
  • Sonora Investment Management left its Denali Therapeutics share count unchanged in Q3 2021.
  • Denali Therapeutics made up ﹤0.01% of Sonora Investment Management's portfolio in Q3 2021, its #517 holding.
  • Sonora Investment Management first reported a position in Denali Therapeutics in Q2 2021 and has held it in 2 quarters since.
  • Sonora Investment Management's Denali Therapeutics position peaked at $49K in Q2 2021.
  • 214 funds tracked by Wall St. Rank held Denali Therapeutics as of Q3 2021.

Based on Sonora Investment Management's 13F filing for Q3 2021, filed 12 Nov 2021.